Patents by Inventor Thierry Groblewski

Thierry Groblewski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYCLOPROPYL AMIDE DERIVATIVES
    Publication number: 20150216861
    Abstract: Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.
    Type: Application
    Filed: April 13, 2015
    Publication date: August 6, 2015
    Inventors: James Arnold, Andrew Todd Brugel, Scott Throner, Steven Wesolowski, Phil Edwards, Andrew Griffin, Thierry Groblewski, Denis Labrecque
  • Cyclopropyl amide derivatives
    Patent number: 9029381
    Abstract: Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: May 12, 2015
    Assignee: Astrazeneca AB
    Inventors: James Arnold, Todd Andrew Brugel, Scott Throner, Steven Wesolowski, Phil Edwards, Andrew Griffin, Thierry Groblewski, Denis Labrecque
  • Cyclopropyl Amide Derivatives '978
    Publication number: 20120065193
    Abstract: Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.
    Type: Application
    Filed: November 21, 2011
    Publication date: March 15, 2012
    Inventors: James Arnold, Andrew Todd Brugel, Scott Throner, Steven Wesolowski, Phil Edwards, Andrew Griffin, Thierry Groblewski, Denis Labrecque
  • Cyclopropyl amide derivatives
    Patent number: 8063215
    Abstract: Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.
    Type: Grant
    Filed: August 21, 2008
    Date of Patent: November 22, 2011
    Assignee: AstraZeneca AB
    Inventors: James Arnold, Todd Andrew Brugel, Scott Throner, Steven Wesolowski, Phil Edwards, Andrew Griffin, Thierry Groblewski, Denis Labrecque
  • Spirocyclopropyl Piperidine Derivatives
    Publication number: 20100168105
    Abstract: Disclosed herein is at least one piperidine derivative, at least one pharmaceutical composition comprising at least one piperidine derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith
    Type: Application
    Filed: May 23, 2008
    Publication date: July 1, 2010
    Inventors: Peter Bernstein, Dean Brown, Joseph Cacciola, Phil Edwards, James Folmer, Thierry Groblewski, Mark Sylvester, Steven Wesolowski
  • Cyclopropyl Amide Derivatives 978
    Publication number: 20090076020
    Abstract: Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.
    Type: Application
    Filed: August 21, 2008
    Publication date: March 19, 2009
    Applicant: ASTRAZENECA AB
    Inventors: James Arnold, Todd Andrew Brugel, Scott Throner, Steven Wesolowski, Phil Edwards, Andrew Griffin, Thierry Groblewski, Denis Labrecque
  • ASSAYS
    Publication number: 20080064046
    Abstract: The present invention is directed to assays that can be used to screen for compounds that act as agonists or antagonists or inverse agonists of bovine adrenal medulla docosapeptide (BAM-22P). The assays are based upon the binding of BAM-22P to the rat and human DRR receptors.
    Type: Application
    Filed: August 14, 2007
    Publication date: March 13, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Sultan Ahmad, Eric Grazzini, Thierry Groblewski, Paola Lembo, Ralf Schmidt
  • Assays to screen for compounds that bind the dorsal root receptor
    Patent number: 7270965
    Abstract: The present invention is directed to assays that can be used to screen for compounds that act as agonists or antagonists or inverse agonists of bovine adrenal medulla docosapeptide (BAM-22P). The assays are based upon the binding of BAM-22P to the rat and human DRR receptors.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: September 18, 2007
    Assignee: AstraZeneca AB
    Inventors: Sultan Ahmad, Eric Grazzini, Thierry Groblewski, Paolo Lembo, Ralf Schmidt
  • SPLICE VARIANT CANNABINOID RECEPTOR (CB1B)
    Publication number: 20070117138
    Abstract: The invention is based on the identification of a novel splice variant of human cannabinoid 1 (CB1) receptor, termed CB1b, and its use in the identification of therapeutic agents and in the diagnosis, prevention and treatment of CB associated disorders such as obesity, psychiatric, pain and neurological disorders.
    Type: Application
    Filed: January 11, 2007
    Publication date: May 24, 2007
    Applicant: ASTRAZENECA AB
    Inventors: Huy Vu, Thierry Groblewski, Peter Greasley
  • Screening assays for cannabinoid-ligand-type modulators of gpr55
    Publication number: 20060194260
    Abstract: Screening assays for compounds that modulate the interaction between cannabinoids and the GPR55 receptor are disclosed. Furthermore, a method for determining the selectivity of a test compound against a panel of cannabinoid receptors including GPR55 is disclosed.
    Type: Application
    Filed: February 13, 2004
    Publication date: August 31, 2006
    Applicant: AstraZeneca AB
    Inventors: Tomas Drmota, Peter Greasley, Thierry Groblewski
  • Splice variant cannabinoid receptor (cb1b)
    Publication number: 20060115816
    Abstract: The invention is based on the identification of a novel splice variant of human cannabinoid 1 (CB1) receptor, termed CB1b, and its use in the identification of therapeutic agents and in the diagnosis, prevention, and treatment of CB associated disorders such as obesity, psychiatric, pain and neurological disorders.
    Type: Application
    Filed: July 14, 2003
    Publication date: June 1, 2006
    Applicant: AstraZeneca A B
    Inventors: Huy Vu, Thierry Groblewski, Peter Greasly
  • Assays
    Publication number: 20050059575
    Abstract: The present invention is directed to assays that can be used to screen for compounds that act as agonists or antagonists or inverse agonists of bovine adrenal medulla docosapeptide (BAM-22P). The assays are based upon the binding of BAM-22P to the rat and human DRR receptors.
    Type: Application
    Filed: October 16, 2001
    Publication date: March 17, 2005
    Inventors: Sultan Ahmad, Eric Grazzini, Thierry Groblewski, Paola Lembo, Ralf Schmidt